Jones Financial Companies Lllp Has $45.84 Million Stake in Abbott Laboratories $ABT

Key Points

• Jones Financial Companies Lllp increased its holdings in Abbott Laboratories by 10.5% in Q1, owning 348,852 shares valued at approximately $45.84 million.
• Abbott Laboratories reported $1.26 earnings per share for the last quarter, matching analyst expectations, with a revenue increase of 7.4% year-over-year to $11.14 billion.
• A total of 75.18% of Abbott Laboratories' stock is held by institutional investors, indicating strong institutional interest in the company.

Jones Financial Companies Lllp grew its holdings in Abbott Laboratories (NYSE:ABT - Free Report) by 10.5% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 348,852 shares of the healthcare product maker's stock after purchasing an additional 33,081 shares during the period. Jones Financial Companies Lllp's holdings in Abbott Laboratories were worth $45,837,000 as of its most recent SEC filing.

Several other large investors have also made changes to their positions in ABT. Brighton Jones LLC grew its stake in shares of Abbott Laboratories by 10.1% in the 4th quarter. Brighton Jones LLC now owns 51,719 shares of the healthcare product maker's stock valued at $5,850,000 after buying an additional 4,755 shares in the last quarter. Bank Pictet & Cie Europe AG boosted its position in Abbott Laboratories by 1.9% during the fourth quarter. Bank Pictet & Cie Europe AG now owns 152,719 shares of the healthcare product maker's stock worth $17,274,000 after purchasing an additional 2,774 shares during the period. Toronto Dominion Bank boosted its position in Abbott Laboratories by 2.9% during the fourth quarter. Toronto Dominion Bank now owns 727,351 shares of the healthcare product maker's stock worth $82,269,000 after purchasing an additional 20,457 shares during the period. Strive Asset Management LLC bought a new stake in Abbott Laboratories during the fourth quarter worth approximately $711,000. Finally, State of Wyoming boosted its position in Abbott Laboratories by 661.6% during the fourth quarter. State of Wyoming now owns 6,832 shares of the healthcare product maker's stock worth $773,000 after purchasing an additional 5,935 shares during the period. Institutional investors own 75.18% of the company's stock.

Abbott Laboratories Stock Performance

Abbott Laboratories stock opened at $133.92 on Monday. The company has a debt-to-equity ratio of 0.25, a current ratio of 1.82 and a quick ratio of 1.30. The stock has a fifty day moving average price of $130.41 and a two-hundred day moving average price of $131.25. Abbott Laboratories has a 52-week low of $110.86 and a 52-week high of $141.23. The firm has a market capitalization of $233.08 billion, a P/E ratio of 16.78, a P/E/G ratio of 2.54 and a beta of 0.69.

Abbott Laboratories (NYSE:ABT - Get Free Report) last released its quarterly earnings data on Thursday, July 17th. The healthcare product maker reported $1.26 earnings per share (EPS) for the quarter, hitting the consensus estimate of $1.26. Abbott Laboratories had a return on equity of 18.32% and a net margin of 32.43%.The firm had revenue of $11.14 billion during the quarter, compared to analyst estimates of $11.01 billion. During the same period in the prior year, the company posted $1.14 earnings per share. The business's revenue for the quarter was up 7.4% compared to the same quarter last year. Abbott Laboratories has set its FY 2025 guidance at 5.100-5.200 EPS. Q3 2025 guidance at 1.280-1.320 EPS. As a group, analysts anticipate that Abbott Laboratories will post 5.14 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on ABT shares. Leerink Partnrs raised Abbott Laboratories to a "hold" rating in a research report on Monday, June 16th. Leerink Partners began coverage on Abbott Laboratories in a report on Monday, June 16th. They set a "market perform" rating and a $143.00 price target for the company. Mizuho upped their price target on Abbott Laboratories from $130.00 to $140.00 and gave the stock a "neutral" rating in a report on Wednesday, July 16th. Jefferies Financial Group upgraded Abbott Laboratories from a "hold" rating to a "buy" rating and upped their target price for the company from $143.00 to $145.00 in a research note on Friday, July 18th. Finally, William Blair upgraded Abbott Laboratories to a "strong-buy" rating in a research note on Thursday, July 17th. Two research analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and four have assigned a Hold rating to the company. According to data from MarketBeat.com, Abbott Laboratories has an average rating of "Moderate Buy" and a consensus price target of $144.47.

Insider Transactions at Abbott Laboratories

In other news, CFO Philip P. Boudreau sold 5,550 shares of the stock in a transaction on Friday, August 8th. The stock was sold at an average price of $134.55, for a total transaction of $746,752.50. Following the sale, the chief financial officer owned 51,003 shares in the company, valued at approximately $6,862,453.65. This represents a 9.81% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 0.46% of the stock is owned by corporate insiders.

About Abbott Laboratories

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.